Hostname: page-component-78c5997874-j824f Total loading time: 0 Render date: 2024-11-18T17:18:11.976Z Has data issue: false hasContentIssue false
  • English
  • Français

Nephrotic Syndrome in a Multiple Sclerosis Patient Treated with Interferon β1a

Published online by Cambridge University Press:  02 December 2014

Anthony Auty  and
Abdulkarim Saleh
Anthony Auty*
Affiliation:
Division of Neurology, Department of Medicine, Shaikh Khalifa Medical Centre, Abu Dhabi, United Arab Emirates
Abdulkarim Saleh
Affiliation:
Division of Neurology, Department of Medicine, Shaikh Khalifa Medical Centre, Abu Dhabi, United Arab Emirates
*
Division of Neurology, Department of Medicine, Shaikh Khalifa Medical Centre, PO Box 51900, Abu Dhabi, United Arab Emirates.
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background:

Interferon β has become standard therapy for reducing relapse frequency in relapsing/remitting Multiple Sclerosis (RRMS). Several different preparations are available including interferon β1a (Avonex, Rebif) and interferon β1b (Betaferon/Betaseron). For the most part these preparations have been considered safe. Recently there have been concerns relating to liver1 and now kidney toxicity.

Case Report:

We present a case of a 28-yr old male who developed a severe case of nephrotic syndrome while being treated for relapsing/remitting Multiple Sclerosis (RRMS) with weekly injections of interferon β1a.

Subsequent course:

The nephrosis resolved almost completely once the interferon was stopped and after immunosuppressive treatment. At its peak the daily protein loss was 35.82 g. Kidney biopsy demonstrated membranous glomerulonephritis.

Discussion:

Two other case reports of nephrotic syndrome have been reported in the literature. This latest (third) report suggests that the safety profile should be reexamined and at least raises the question of potential renal toxicity of interferons in MS.

Résumé:

RÉSUMÉ: Introduction:

L’interféron b est devenu le traitement standard pour diminuer la fréquence des récidives dans la sclérose en plaques récurrente/rémittente (SEPRR). Plusieurs préparations différentes sont disponibles don’t l’interféron 1a (Avonex, Rebif) et l’interféron 1b (Betaferon/Betaseron). En général, on considérait que ces préparations étaient sûres. Depuis peu, on s’inquiète de leur toxicité hépatique et maintenant de leur toxicité rénale.

Observation:

Nous rapportons le cas d’un patient de 28 ans, originaire des Émirats arabes unis, qui a développé un syndrome néphritique aigu au cours du traitement de sa SEPRR au moyen d’injections hebdomadaires d’interféron b1a.

Suivi:

La néphrose a presque complètement disparu suite à l’arrêt du traitement et à un traitement immunosuppresseur. En phase aiguë, la perte quotidienne de protéines était de 35,82 g. La biopsie rénale a montré qu’il s’agissait d’une glomérulonéphrite membraneuse.

Discussion:

Deux autres cas de syndrome néphritique ont été rapportés dans la littérature. Ce troisième cas indique que le profil de sécurité des interférons devrait être réexaminé et soulève des questions concernant leur toxicité rénale chez les patients atteints de la SEP.

Type
Case Report
Information
Canadian Journal of Neurological Sciences , Volume 32 , Issue 3 , August 2005 , pp. 366 - 368
Copyright
Copyright © The Canadian Journal of Neurological 2005

References

1. Tremlett, H, Oger, J. Hepatic injury, liver monitoring and beta-interferons for multiple sclerosis. J Neurol 2004; 251:1297–1303.CrossRefGoogle ScholarPubMed
2. Goodin, D, Frohman, E, Garmany, G Jr, et al. Disease modifying therapies in multiple sclerosis. Neurology 2002; 58:169–178.Google ScholarPubMed
3. Dubois, B, Keenan, E, Porter, B, et al. Interferon beta in multiple sclerosis: experience in a British specialist multiple sclerosis centre. JNNP 2003; 74:946–949.Google Scholar
4. Walther, E, Hohlfeld, R. Side effects of interferon beta therapy and their management. Neurology 1999; 53:1622–1627.CrossRefGoogle ScholarPubMed
5. Health Canada Advisory. Important safety information about the risk of liver injury in patient taking beta-interferon therapy. 2003: 2003–2013.Google Scholar
6. Walther, E, Dang, T, Hohlfeld, R. Management of side-effects of beta-interferon therapy in MS. Int MSJ 1999; 5:65–70.Google Scholar
7. Schmidt, S, Shlegel, U, et al. Capillary leak syndrome after interferon‚ b1-b therapy in a patient with MS and monoclonal gammopathy. Akt Neurologie 1998;25:S138.Google Scholar
8. Gotsman, I, Elhallel-Darnitski, M, et al. Beta interferon induced nephrotic syndrome in a patient with multiple sclerosis. Clin Nephrol 2000; 54:425–426.Google Scholar
9. Tola, M, Caniatti, L, et al. Recurrent nephrotic syndrome in a patient with multiple sclerosis treated with interferon beta-1a. J Neurol 2003; 250(6):768–769.CrossRefGoogle Scholar
10. Emsley, H, Molloy, J. Inflammatory demyelinating polyradiculopathy associated with membranous glomerulonephrits and thrombocytopenia. Clin Neurol and Neurosurg 2002; 105:23–26.CrossRefGoogle Scholar
11. Campos, A, Gieron, M, et al. Membranous nephropathy associated with multiple sclerosis. Pediatr Neurol 1993; 9:64–66.CrossRefGoogle ScholarPubMed
12. Henderson, R, Saltissi, D, et al. Goodpasture’s syndrome associated with multiple sclerosis. Acta Neurol Scand 1998; 98:134–135.CrossRefGoogle ScholarPubMed
13. Lo, R, Feasby, TE. Multiple sclerosis and autoimmune diseases. Neurology 1983; 33: 97–98.CrossRefGoogle ScholarPubMed
14. De Keyser, J. Autoimmunity in multiple sclerosis. Neurology 1988; 38:371–373.CrossRefGoogle ScholarPubMed